Phenylurea derivatives as inhibitors of tyrosine kinases for the treatment of tumour diseases

US7696224B2 · kind B2 · utility

Assignee

• Merck Patent GmbH · DE

Inventors

• Wolfgang Staehle · Ingelheim am Rhein, DE
• Guenter Hoelzemann · Seeheim-Jugenheim, DE
• Wilfried Rautenberg · Reinheim, DE

Key dates

• Filing date: Sep 16, 2005
• Grant date: Apr 13, 2010
• Expiry date: Apr 27, 2026

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds of the formula (I), in which R1a—R1e, R2a, R2b, R3 and X have the meanings indicated in claim 1, are inhibitors of tyrosine kinases, in particular TIE-2, and Raf kinases and can be employed, inter alia, for the treatment of tumours.